Newsfeeds Archive - Page 7 of 56

2 minute read

Cybin Launches Five-Day Units Offering For Up To $64M, Suspends Prior LPC Funding Deal

November 10, 3:58 PM

Clinical-stage psychedelics biotech Cybin Inc. (NYSE: CYBN) has announced a new underwritten offering of 66.66 million units to one of its largest institutional shareholders as well as new institutional investors.

CYBN

2 minute read

Canada To Australia: New MDMA & Psilocybin Shipment On Its Way For Legal Therapeutic Market

By Lara Goldstein

November 8, 12:34 PM

The first of several of PharmAla Biotech’s (OTC: PMBHF) shipments of psychedelic molecules -both API and finished drug product capsules- to its Australian JV Cortexa for use under the Authorized Prescriber Scheme (

PMBHF

3 minute read

Psyched: DEA’s Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More

By Lara Goldstein

November 6, 8:02 PM

DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court

ATAI

2 minute read

MindMed Q3 2023: Financials, Business Funded By 2026 If LSD Pipeline Milestones Achieved

By Lara Goldstein

November 3, 2:12 PM

Clinical-stage psychedelics biotech Mind Medicine (MindMed) (NASDAQ: MNMD) has shared its financial outcomes for the third quarter ended September 30, 2023. In numbers:

MNMD

3 minute read

COMPASS Pathways Q3 2023 Results: Cash Injection To Sustain Phase 3 Psilocybin Program

By Lara Goldstein

November 2, 2:16 PM

COMPASS Pathways plc (NASDAQ: CMPS), the London-headquartered psychedelics biotech company reported financial results for the third quarter 2023 ended September 30, showing:

CMPS

2 minute read

Single Dose Of Cybin’s Psilocybin Shows Compelling Patient Outcomes, Phase 2 Results Find

By Lara Goldstein

November 1, 4:51 PM

Psychedelics company Cybin Inc. (NYSE: CYBN) shared its Phase 2 study interim results for its psilocybin analog CYB003

CYBN

4 minute read

Psyched: Cybin’s Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney’s Memoirs And More

By Lara Goldstein

October 29, 10:48 PM

Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted

ATAI

3 minute read

EXCLUSIVE: Expert Advice On How To Become Compliant Psychedelics Cultivator And Manufacturer

By Lara Goldstein

October 27, 11:41 AM

What can businesses and clients expect from psychedelic-assisted therapies (PAT)? What are state regulations looking like from a for-profit perspective and what does it take to provide safe, effective and compliant treatments?

AMZN

2 minute read

Cybin’s Deuterated Psychedelics Programs Protected By Three New International Patents

By Lara Goldstein

October 26, 5:21 PM

Cybin’s (NYSE: CYBN) deuterated psychedelics programs received two patent grants from the United States Patent and Trademark Office (USPTO,) and one from the European Patent Office (EP.)

CYBN